Celldex Therapeutics, Inc. (CLDX) Cash and securities
- Total cash · latest quarter (USD): Value $717.59M; Formula and calculation Cash and cash equivalents plus current marketable securities. Period ending 2026-06-30..
- Cash per share · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-06-30..
Cash and securities
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total cash · latest quarter (USD) | $717.59M | Cash and cash equivalents plus current marketable securities. Period ending 2026-06-30. $47.45M + $670.13M ≈ $717.59M |
| Cash per share · latest quarter | (m) | Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash and equivalents | 47.45M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 670.13M USD | Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Cash and current securities | 717.59M USD | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total cash | Cash per share | Cash and equivalents (USD) | Short-term securities (USD) | Quarter-end shares (shares) |
|---|---|---|---|---|---|
| 2026-06-30 | $717.59M | (m) | $47.45M | $670.13M | (m) |
| 2026-03-31 | $451.46M | (m) | $35.73M | $415.73M | (m) |
| 2025-12-31 | $518.57M | (m) | $28.87M | $489.70M | (m) |
| 2025-09-30 | $583.22M | (m) | $36.04M | $547.19M | (m) |
| 2025-06-30 | $630.34M | (m) | $23.04M | $607.29M | (m) |
| 2025-03-31 | $673.29M | (m) | $17.14M | $656.15M | (m) |
| 2024-12-31 | $725.28M | (m) | $28.36M | $696.92M | (m) |
| 2024-09-30 | $756.00M | (m) | $36.40M | $719.60M | (m) |
| 2024-06-30 | $802.32M | (m) | $42.74M | $759.58M | (m) |
| 2024-03-31 | $823.85M | (m) | $115.08M | $708.77M | (m) |
| 2023-12-31 | $423.60M | (m) | $34.81M | $388.78M | (m) |
| 2023-09-30 | $235.35M | (m) | $21.13M | $214.21M | (m) |
| 2023-06-30 | $252.70M | (m) | $28.22M | $224.47M | (m) |
| 2023-03-31 | $278.39M | (m) | $54.12M | $224.26M | (m) |
| 2022-12-31 | $304.95M | (m) | $29.43M | $275.52M | (m) |
| 2022-09-30 | $323.47M | (m) | $18.58M | $304.89M | (m) |
| 2022-06-30 | $356.82M | (m) | $28.40M | $328.42M | (m) |
| 2022-03-31 | $380.47M | (m) | $25.29M | $355.18M | (m) |
| 2021-12-31 | $408.25M | (m) | $39.14M | $369.11M | (m) |
| 2021-09-30 | $423.09M | (m) | $72.18M | $350.90M | (m) |
| 2021-06-30 | $164.04M | (m) | $43.45M | $120.59M | (m) |
| 2021-03-31 | $176.08M | (m) | $69.31M | $106.77M | (m) |
| 2020-12-31 | $194.42M | (m) | $43.84M | $150.59M | (m) |
| 2020-09-30 | $199.59M | (m) | $18.15M | $181.44M | (m) |
| 2020-06-30 | $206.91M | (m) | $68.03M | $138.89M | (m) |
| 2020-03-31 | $53.72M | (m) | $22.72M | $31.00M | (m) |
| 2019-12-31 | $64.38M | (m) | $11.23M | $53.15M | (m) |
| 2019-09-30 | $72.92M | (m) | $16.59M | $56.33M | (m) |
| 2019-06-30 | $81.34M | (m) | $19.74M | $61.60M | (m) |
| 2019-03-31 | $85.07M | (m) | $31.53M | $53.53M | (m) |
| 2018-12-31 | $94.02M | (m) | $24.31M | $69.71M | (m) |
| 2018-09-30 | $105.62M | (m) | $32.82M | $72.80M | (m) |
| 2018-06-30 | $114.01M | (m) | $43.89M | $70.11M | (m) |
| 2018-03-31 | $123.25M | (m) | $39.82M | $83.42M | (m) |
| 2017-12-31 | $139.43M | (m) | $40.29M | $99.14M | (m) |
| 2017-09-30 | $140.53M | (m) | $54.73M | $85.80M | (m) |
| 2017-06-30 | $153.98M | (m) | $66.16M | $87.82M | (m) |
| 2017-03-31 | $167.02M | (m) | $42.50M | $124.53M | (m) |
| 2016-12-31 | $189.78M | (m) | $42.46M | $147.31M | (m) |
| 2016-09-30 | $203.25M | (m) | $31.74M | $171.50M | (m) |
| 2016-06-30 | $220.13M | (m) | $32.48M | $187.65M | (m) |
| 2016-03-31 | $254.02M | (m) | $63.02M | $190.99M | (m) |
| 2015-12-31 | $289.89M | (m) | $72.11M | $217.78M | (m) |
| 2015-09-30 | $304.61M | (m) | $66.79M | $237.82M | (m) |
| 2015-06-30 | $333.99M | (m) | $81.58M | $252.41M | (m) |
| 2015-03-31 | $359.77M | (m) | $122.17M | $237.60M | (m) |
| 2014-12-31 | $201.04M | (m) | $28.02M | $173.02M | (m) |
| 2014-09-30 | $224.08M | (m) | $32.52M | $191.55M | (m) |
| 2014-06-30 | $252.37M | (m) | $40.80M | $211.57M | (m) |
| 2014-03-31 | $274.23M | (m) | $56.90M | $217.32M | (m) |
| 2013-12-31 | $302.98M | (m) | $169.40M | $133.58M | (m) |
| 2013-09-30 | $136.59M | (m) | $14.63M | $121.96M | (m) |
| 2013-06-30 | $154.98M | (m) | $25.90M | $129.08M | (m) |
| 2013-03-31 | $182.38M | (m) | $75.63M | $106.75M | (m) |
| 2012-12-31 | $83.96M | (m) | $24.90M | $59.06M | (m) |
| 2012-09-30 | $77.61M | (m) | $23.19M | $54.43M | (m) |
| 2012-06-30 | $78.67M | (m) | $18.56M | $60.11M | (m) |
| 2012-03-31 | $92.13M | (m) | $22.75M | $69.37M | (m) |
| 2011-12-31 | $53.31M | (m) | $11.90M | $41.41M | (m) |
| 2011-09-30 | $62.77M | (m) | $13.10M | $49.68M | (m) |
| 2011-06-30 | $71.24M | (m) | $10.83M | $60.41M | (m) |
| 2011-03-31 | (m) | (m) | $10.14M | (m) | (m) |
| 2010-12-31 | $61.10M | (m) | $21.29M | $39.81M | (m) |
| 2010-09-30 | (m) | (m) | $9.83M | (m) | (m) |
| 2010-06-30 | (m) | (m) | $15.16M | (m) | (m) |
| 2009-12-31 | (m) | (m) | $57.00M | (m) | (m) |
| 2008-12-31 | (m) | (m) | $44.26M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |